medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2002, Número 3

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2002; 49 (3)


Mecanismos de reconocimiento humoral en el xenotrasplante de órganos sólidos: I. Revisión del rechazo hiperagudo

Arteaga TG, Guerra-Infante FM

Idioma: Español
Referencias bibliográficas: 60
Paginas: 130-140
Archivo PDF: 86.86 Kb.


RESUMEN

El trasplante de tejidos vascularizados entre especies filogenéticamente distantes ocasiona que tales tejidos sean rápida y violentamente destruidos mediante el proceso denominado rechazo hiperagudo. En algunas combinaciones de cerdo y primate el rechazo del injerto es iniciado por el reconocimiento de anticuerpos del receptor a los antígenos presentes en los vasos sanguíneos del donador. Los anticuerpos unidos a los blancos antigénicos activan al complemento, el cual potencializa el evento patogénico. La xenorreactividad observada en el rechazo hiperagudo varía sustancialmente de experimento a experimento y de especie a especie, existe relativa investigación en la variación de la expresión de los blancos antigénicos en la población de los potenciales donadores porcinos. Tales cuantificaciones podrán tener muchas implicaciones para el xenotrasplante debido a que la variabilidad de la expresión de los antígenos permitiría la evaluación experimental de los donadores que identificaran los pares con menor reactividad. Esta revisión permite examinar los mecanismos de rechazo hiperagudo observados en la experimentación xenogénica entre animales y humanos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1 . Cooper DKC, Groth CG, McKenzie IFC. Xenotransplantation: This new form of treatment might benefit millions. BMJ 2000; 320(7238): 868.

  2. Reemtsma K, McCracken BH, Schlegel JU, Pearl MA, Pearce WC et al. Renal heterotransplantation in man. Ann Surg 1964; 160:384-410.

  3. Michaels MG, Simmons RL. Xenotransplant associated zoonoses: strategies for prevention. Transpl 1994; 57: 1-7.

  4. Fung J. Xenotransplantation. Subhuman primates as donors. Path Biol 1994; 42(3): 221-223.

  5. Auchincloss H Jr. Xenogeneic transplantation: a review. Transpl 1988; 46: 1-20.

  6. Niekrasz M, Ye Y, Rolf LL. The pig as organ donor for man. Transplant Proc 1992; 24: 625-626.

  7. Sachs HD. The pig as a xenograft donor. Path Biol 1994; 42(3): 217-219.

  8. Cozzi E, White GJD. The generation of transgenic pigs as potential organs donors for humans. Nat Med 1995; 1(9): 964-966.

  9. Neuzil DF, Rozga J, Demetriai AA, Moscioni AD, Ro MS et al. Use of a novel bioartificial liver in a patient with acute liver insufficiency. Surg 1993; 113: 340-343.

  10. Makowa L, Cramer VD, Hoffman A, Breda M, Sheen L et al. The use of a pig liver xenograft for temporary support of patient with fulminant hepatic failure. Transpl 1995; 59(12): 1654-1659.

  11. McMorrow IM, Cornrack CA, Nazarey PP, Sachs DH, DerSimonian H. Relationship between AB0 blood group and levels of Gal a3 Galactose-reactive human immunoglobulin G. Transpl 1997; 64(3): 546-549.

  12. Ogden D, Sitprija V, Holmes J. Function on the baboon renal heterograft in man and comparation with renal homograft function. J Lab Clin Med 1965; 65(3): 370-386.

  13. Hardy JD, Chavez CM, Kurrus FD. Heart transplantation in man: Developmental studies and report of a case. Jam Med Assoc 1964; 188: 1132.

  14. Bailey LL, Nehlsen-Cannarella SL, Concepcion W, Jolley WB. Baboon to human cardiac xenotransplantation in a neonate. J Am Med Assoc 1985; 254: 3321-3329.

  15. Giles G, Boehmig H, Amemiya H, Halgrimson C, Starzl T. Clinical heterotransplantation of the liver. Transplant Proc 1970; 2(4): 506-512.

  16. Metcalfe S. Immunomodulation for transplantation tolerance. Eye 1995; 9: 192-195.

  17. Starzl ET, Fung J, Tzakis A, Todo S, Demetris JA et al. Baboon to human liver transplantation. Lancet 1993; 341: 65-71.

  18. Bach FH, Robson CS, Ferran C, Winkler H, Millan TM et al. Endothelial cell activation and throboregulation during xenograft rejection. Immunol Rev 1994; 141: 5-30.

  19. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2: 550-553.

  20. Starzl ET, Marchioro TL, Peters G, Kirkpatric CH, Wilson WEC et al. Renal heterotransplantation from baboon to man: experience with 6 cases. Transpl 1964; 2: 752-776.

  21. Vanhove B, Bach FH. Human xenoreactive natural antibodies-avidity and targets on porcine endothelial cells. Transpl 1993; 56: 1251-1255.

  22. Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FJ. Endothelial cell antigens recognized by xenoreactive human natural antibodies. Transpl 1990; 50: 817-822.

  23. Gambiez L, Salame E, Chereau C, Calmus Y, Carsoso J et al. The role of natural IgM in the hyperacute rejection of discordant heart xenografts. Transpl 1992; 54: 577-583.

  24. Fischel RJ, Matas AJ, Perry E, Dalmasso A, Noreen H et al. Plasma exchange, organ perfusion and immunosuppression reduce “natural” antibodie levels as measured by binding to xenogeneic endothelial cells and prolong discordant xenograft survival. Transplant Proc 1992; 24: 574-575.

  25. Roslin MS, Zisbrod Z, Burack JH. Tranbaugh RF, Strashun A et al. Fifteen day survival in pig to baboon heterotopic cardiac transplantation. Transplant Proc 1992; 24: 572-573.

  26. Alvarado GC, Cotterell HA, McCurry RK, Collins HB, Magee CJ et al. Variation in the level of xenoantigen expression in porcine organs. Transpl 1995; 59(11): 1589-1596.

  27. Geller RL, Rubinstein P, Platt JL. Variation in expression of porcine xenogeneic antigens. Transpl 1994; 58: 271-277.

  28. Platt JL, Holzknecht ZE. Porcine platelet antigens recognized by human xenoreactive natural antibodies. Transpl 1994; 57: 327-335.

  29. Cooper CKD, Koren E, Oriol R. Oligosaccharides and discordant xenotransplantation. Immunol Rev 1994; 141: 31-58.

  30. Galili U. Interaction of the natural anti Gal antibody with (a-galactosil epitopes: a mayor obstacle for xenotransplantation in humans. Immunol Today 1993; 14: 480-482.

  31. Good H, Cooper DKC, Malcom AJ, Ippolito RM, Koren E et al. Identification of carbohydrate structures which bind human anti-porcine antibodies: implications for discordant xenografting in man. Transplant Proc 1992; 24: 559-562.

  32. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. The interaction between the human natural anti-a-galactosyl IgG (anti-Gal) and bacteria of the human flora. Infect Immunol 1988; 57: 1730-1735.

  33. McMorrow I, Comrack C, Sach DH, DerSimonian H. Crossreactivity of human anti-pig IgG and IgM natural antibodies with alpha 1, 3 Gal. Transpl 1996; 28: 547.

  34. Cooper DK, Good AH, Koren E et al. ldentification of alpha-galactosyl and other carbohidrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1: 198.

  35. Luderitz O, Simmons DAR, Westphal O. The immunochemistry of Salmonella hemotype VI O-antigen. The structure of oligosaccharides from Salmonella group V 04 lipopolysaccharides. Biochem J 1965; 97: 820-824.

  36. Jansson PE, Lindberg AA, Lindberg B, Walling R. Structural studies on the hexose region of the core lipopolysaccharide from entero bacteriaceae. Eur J Biochem 1981; 115: 571-574.

  37. Geyer R, Geyer H, Strem S, Hunsmann G, Schneider J et al. Major oligosaccharides in the glycoprotein of friend murine leukemia virus: structure elucilation by one-and two-dimensional proton nuclear magnetic resonance and methylation analysis. Biochem 1984; 23: 5628-5633.

  38. Avila JL, Rojas M, Galili U. Immunogenic Gal-a1-3Gal carbohydrate epitopes are present on pathogenic american Trypanosoma and Leishmania. J Immunol 1989; 142: 2828.

  39. Towbin H, Rosenfelder G, Wieslander J, Avila JL, Rojas M et al. Circulating antibodies to mouse laminin in Chagas disease, American Cutaneous Leishmaniasis and normal individuals recognize terminal galactosyl a(1-3) galactose epitopes. J Exp Med 1987; 166: 419-425.

  40. Gabrielli A, Leoni P, Danieli G, Hermann K, Krieg T et al. Antibodies against galactosyl a(1-3) galactose in connective tissue disease. Arthritis Rheum 1991; 34: 375.

  41. Gabrielli A, Cundela M, Pisani E, Hermann K, Wieslander J et al. Antibodies against terminal galactosyl a(1-3) galactose epitopes in systemic sclerosis (scleroderma). Clin Exp Rheumatol 1992; 10: 31-35.

  42. Leoni P, Rupoli S, Salvi A, Sambo P, Cinciripini A et al. Antibodies against terminal galactosyl a(1-3) galactose epitopes in patients with idiopathic myelofibrosis. Br J Haematol 1993; 85: 313-320.

  43. Johnston PS, Lim SML, Wang MW. Hyperacute rejection of xenografts in the complet absence of antibody. Transplant Proc 1991; 23: 877-879.

  44. Pruitt SK, Baldwin WM. 3ro. and Marsh HC Jr. The effect of soluble complement receptor type 1 on hiperacute xenograft rejection. Transpl 1991; 52: 868-873.

  45. Geller RL, Bach FH, Vercellotti GM, Nistler RS, Bolman RM 3ro. et al. Activation of endothelial cells in hyperacute xenograft rejection. Transplant Proc 1992; 24: 592.

  46. Takeshita K, Arakawa K, Okamoto M, Akioka K, Fujiwara Y et al. The anticoagulant effect of antithrombin III on hyperacute xenograft rejection. Transplant Proc 1996; 28(2): 631-632.

  47. Thomas H, Maillet F, Letourneur D, Jozefonvicz J, Fisher E et al. Sulfonated dextran inhibits complement activation an complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol Immunol 1996; 33(7/8): 643-648.

  48. Kobayashi T, Taniguchi S, Ye Y, Niekrasz M, Kosanke S et al. Delayed xenograft rejection in C3-depleted discordand (pig-to-baboon) cardiac xenograft treated with Cobra Venom Factor. Transpl Procc 1990; 28(2): 560.

  49. Adachi H, Rosengard BR, Hutchins TS, Baumgartner WA, Borkon AM. Effects of cyclosporin, aspirin, and cobra venom factor on discordant xenograft survival in rats. Transplant Proc 1987; 19: 1145-1148.

  50. Kemp E, Steinbruchel D, Starklint H, Larsen S, Henriksen I et al. Renal xenograft rejection: prolonging efect of captopril, ACE inhibitors, prostacyclin, and cobra venom factor. Transplant Proc 1987; 19: 4471-4474.

  51. Miyagawa S, Hirose H, Shirakura R. The mechanism of discordant xenograft rejection. Transpl 1988; 46: 825-830.

  52. Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ et al. Prolongation of cardiac xenograft survival by depletion of complement. Transpl 1993; 55: 857-866.

  53. Dalmasso AP, Platt JL. Prevention of complement mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transpl 1993; 56: 1171-1176.

  54. Cary N, Moody N, Yannoutsos N, Wallwork J, White GJD. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 1993; 25: 400-401.

  55. McCurry RK, Kooyman LD, Alvarado GC, Cotterell HA, Martin JM et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1(5): 423-427.

  56. White GJD, Cozzi E, Langford G, Oglesby T, Wang WM et al. The control of hyperacute rejection by genetic engineering of the donor species. Eye 1995; 9: 185-189.

  57. Akami T, Arakawa K, Okamoto M. The role of human CD59 antigens in discordant xenotransplantation between humans and nonprimates. Transplant Proc 1993; 25: 394-395.

  58. Brauer RB, Baldwin WM 3dr., Daha MR, Pruitt SK, Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993, 151(12): 7240-7248.

  59. Diamond LE, McCurry KR, Martin MJ, McClellan SB, Olldham ER et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transpl 1996; 61(8): 1241-1249.

  60. Diamond LE, Quinn CM, Martin MJ, Lawson J, Platt JL et al. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transpl 2001; 71(1): 132-142.




2020     |     www.medigraphic.com